An independent international multicentre study of Stockholm3, led by Professor Derya Tilki, received the Best Abstract award in the session on diagnostic and prognostic biomarkers for prostate cancer at the European Association of Urology (EAU) annual congress 2025, held in Madrid on 21–24 March.
The award-winning abstract presented real-world clinical results for Stockholm3 outside Scandinavia, where most of the earlier clinical data for Stockholm3 has historically been generated. The study included more than 1,000 men at five centres in Germany, Switzerland and Turkey and compared Stockholm3 with PSA-based screening for detecting clinically significant prostate cancer (csPC). The results showed improved specificity and sensitivity across different European healthcare settings.
Key results included:
-
Among men with PSA levels between 1.5–3 ng/ml, Stockholm3 identified csPC in 32% of those biopsied – cancer cases that would probably have been missed with PSA alone
-
27% fewer unnecessary positive tests when Stockholm3 ≥ 11 was compared with PSA ≥ 3 ng/ml
-
A 3% increase in the detection of csPC (ISUP grade ≥ 2)
-
Fewer low-risk cancer cases (ISUP 1) and fewer benign biopsies, improving diagnostic precision
“This study shows that Stockholm3 not only improves the diagnosis of prostate cancer in Scandinavian populations but also performs well in other European healthcare systems,” says Professor Derya Tilki, principal investigator of the study and physician at the Martini-Klinik Prostate Cancer Center at the University Medical Center Hamburg-Eppendorf.
The results reinforce the importance of Stockholm3 in supporting more accurate decisions on MRI and biopsy and in optimising care pathways for men at risk of prostate cancer.
The study adds to the growing international evidence that Stockholm3 can transform the early detection of aggressive prostate cancer, reduce overdiagnosis and address global challenges in prostate cancer diagnostics.
For more information, visit A3P's website.
